Cerus Corporation (CERS) Financial Analysis & Valuation | Quarter Chart
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pa... more
Cerus Corporation operates as a biomedical products company. The company focuses on developing and c... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $469.55M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Vivek K. Jayaraman |
| IPO Date | 1997-01-31 | CAGR | 12.9% |
| Employees | 268 | Website | www.cerus.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CERS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $639.07M | P/E | -77.41 | Forward P/E | -466 | PEG | — |
| P/S | 13227.89 | P/B | 42094.6 | P/CF | 1232382.73 | P/FCF | -1653251.52 |
| Sales | $227.78M | Sales 1Y | 18.32% | Sales 3Y | 48.46% | Sales 5Y | 113.54% |
| EPS | $-0.03 | EPS 1Y | -68.63% | EPS 3Y | -88.99% | EPS 5Y | -91.26% |
| Sales QoQ | -4.09% | EPS QoQ | — | Sales QoQ Avg | 2.42% | EPS QoQ Avg | 2797.01% |
| Gross Margin | 53.36% | Operating Margin | -3.71% | Profit Margin | -2.98% | ROCE | -7.07% |
| ROA | -3% | ROE | -10% | Altman Z Score | -3.11 | Piotroski Score | 4 |
| Current Ratio | 1.83 | Quick Ratio | 1.07 | Cash Ratio | 0.21 | Op. CF Ratio | -0.03 |
| Debt/Equity | 0.59 | Debt/Assets | 0.2 | Lt Debt/Equity | 0.12 | Lt Debt/Cap. | 0.11 |
| Intrst Cov. | -2.07 | Inventory Turnover | 1.61 | Asset Turnover | 1.11 | Receivables Turnover | 7.35 |
| Enterprise Value | $639.07M | P/E Ratio | -77.41 |
| Forward P/E | -466 | PEG Ratio | — |
| P/S Ratio | 13227.89 | P/B Ratio | 42094.6 |
| P/CF Ratio | 1232382.73 | P/FCF Ratio | -1653251.52 |
| EPS | $-0.03 | EPS Growth 1Y | -68.63% |
| EPS Growth 3Y | -88.99% | EPS Growth 5Y | -91.26% |
| Revenue Growth 1Y | 18.32% | Gross Margin | 53.36% |
| Operating Margin | -3.71% | Profit Margin | -2.98% |
| ROE | -10% | ROA | -3% |
| ROCE | -7.07% | Current Ratio | 1.83 |
| Quick Ratio | 1.07 | Cash Ratio | 0.21 |
| Debt/Equity | 0.59 | Interest Coverage | -2.07 |
| Altman Z Score | -3.11 | Piotroski Score | 4 |
Cerus Corporation (CERS) valuation & financials
Cerus Corporation (CERS) has a market capitalization of $469.55M and trades at a price-to-earnings ratio of -77.4. It operates in the Healthcare sector (Medical - Devices).
Cerus Corporation's revenue grew +18.3% over the last year.
Cerus Corporation's next earnings report is scheduled for November 2, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.01. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)